Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis

  • Koh, Won-Jung; 
  • Kwon, O. Jung; 
  • Gwak, Hyesun; 
  • Chung, Joo Won; 
  • Cho, Sang-Nae; 
  • 외 2명
Citations

WEB OF SCIENCE

87
Citations

SCOPUS

98

초록

Although previous studies have suggested that linezolid may be effective for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB), the optimal dose of linezolid for intractable MDR/XDR-TB is not clear. Twenty-four patients with intractable MDR/XDR-TB were treated with a daily 300 mg dose of linezolid as part of their anti-TB drug regimen. The patients were treated with linezolid for a median duration of 359 days [interquartile range (IQR) 268-443 days]. Seventeen (71%) patients received 300 mg of linezolid once daily from the beginning of treatment for a median duration of 289 days (IQR 233-405 days). Of these patients, four developed peripheral neuropathy, one of whom discontinued linezolid. In seven (29%) patients, 600 mg/day linezolid was administered initially for a median duration of 104 days (IQR 26-145 days) followed by 300 mg/day linezolid for a median duration of 348 days (IQR 298-427 days). In five of these seven patients, the reason for changing from 600 to 300 mg/day was due to side effects of 600 mg/day linezolid (peripheral neuropathy in four patients and leucopenia in one patient). After reducing the dose to 300 mg/day, linezolid could be continued in six of the seven patients. Negative sputum conversion was achieved in 22 (92%) patients after a median of 89 days from the start of linezolid treatment (IQR 48-160 days). A daily 300 mg dose of linezolid may be useful for increasing the chances of culture conversion in the treatment of patients with intractable MDR/XDR-TB and might have fewer side effects, especially neurotoxicity, compared with a daily 600 mg dose of linezolid therapy. The present results encourage further research into the use of a 300 mg dose of linezolid for MDR/XDR-TB patients.

키워드

MDR-TB; XDR-TB; oxazolidinones; efficacy; tolerability; MITOCHONDRIAL PROTEIN-SYNTHESIS; TREATMENT OUTCOMES; INHIBITION; EFFICACY
제목
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis
저자
Koh, Won-Jung; Kwon, O. Jung; Gwak, Hyesun; Chung, Joo Won; Cho, Sang-Nae; Kim, Woo Sung; Shim, Tae Sun
DOI
10.1093/jac/dkp171
발행일
2009-08
유형
Article; Proceedings Paper
저널명
Journal of Antimicrobial Chemotherapy
권
64
호
2
페이지
388 ~ 391